Long-Term Treatment with GM-CSF in Patients with Chronic Lymphocytic Leukemia and Recurrent Neutropenic Infections

References

• Twomey J J. Infections complicating multiple myeloma and chronic lymphocytic leukemia. Arch Intern Med 1973; 132: 562–565
   PubMed Web of Science ®Google Scholar
• Itala M, Helenius H, Nikoskelainen J, Remes K. Infections and serum IgG levels in patients with chronic lymphocytic leukemia. Eur J Haematol 1992; 48: 266–270
   PubMed Web of Science ®Google Scholar
• Bunch C, Chapel H, Gale R P. Infectious complications in chronic lymphocytic leukemia. Chronic Lymphocytic Leukemia, A Polliack, D Catovsky. Harwood Academic Publ, London 1988; 249–262
   Google Scholar
• Molica S. Infections in chronic lymphocytic leukemia: Risk factors and impact on survival and treatment. Leuk Lymph 1994; 13: 203–214
   PubMed Web of Science ®Google Scholar
• Coffey R G. Mechanisms of GM-CSF stimulation of neutrophils. Immunol Res 1989; 8: 236–248
   PubMed Web of Science ®Google Scholar
• Lieschke G J, Burgess A W. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N Engl J Med 1992; 327: 28–35, 99–106
   PubMed Web of Science ®Google Scholar
• Rapoport A P, Abboud C N, Dipersio J F. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF): Receptor biology, signal transduction, and neutrophil activation. Blood Rev 1992; 6: 43–57
   PubMed Web of Science ®Google Scholar
• Trentin L, Zambello R, Agostini C, Enthammer C, Cerutti A, Adami F, Zamboni S, Semenzato G. Expression and regulation of tumor necrosis factor, interleukin-2, and hematopoietic growth factor receptors in B-cell chronic lymphocytic leukemia. Blood 1994; 84: 4249–4256
   PubMed Web of Science ®Google Scholar
• Perez H D, Lipton M, Goldstein I M. A spesific inhibitor of complement (C5)-derived chemotactic activity in serum from patients with systemic lupus erythematosus. J Clin Invest 1978; 62: 29–38
   PubMed Web of Science ®Google Scholar
• Robinson P, Wakerfield D, Breit S N, Easter J F, Penny R. Chemiluminescent response to pathogenic organisms: normal human polymorphonuclear leukocytes. Inf Immun 1984; 43: 744–752
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj S, Velasquez W S, Butler J J, Lemaistre A, Lepe-Zuniga J, Keating M J, Roller C A, Gutterman J U. Stimulation of myelopoiesis in chronic lymphocytic leukemia and in other lymphoproliferative disorders by recombinant human granulocyte-macrophage colony-stimulating factor. Am J Hematol 1990; 33: 189–197
   PubMed Web of Science ®Google Scholar
• Hollander A AMJ, Kluin-Nelemans H C, Haak H R, Stern A C, Willemze R, Fibbe W E. Correction of neutropenia associated with chronic lymphocytic leukaemia following treatment with granulocyte-macrophage colony-stimulating factor. Case report. Ann Hematol 1991; 62: 32–34
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Talpaz M, Gomez J A, Estey E H, O'Brien S, Hirsch-Ginsberg C, Koller C, Freireich E J, Gutterman J U. Differential dose-related haematological effects of GM-CSF in pancytopenia: evidence supporting the advantage of low-over high-dose administration in selected patients. Br J Haematol 1991; 78: 352–358
   PubMed Web of Science ®Google Scholar
• Weisbart R H, Kwan L, Golde D W, Gasson J C. Human GM-CSF primes neutrophils for enhanced oxidative metabolism in response to the major physiological chemoattractants. Blood 1987; 69: 18–21
   PubMed Web of Science ®Google Scholar
• Khwaja A, Carver J E, Linch D C. Interactions of granulocyte-macrophage colony-stimulating factor (CSF), granulocyte CSF, and tumor necrosis factor in the priming of the neutrophil respiratory burst. Blood 1992; 79: 745–753
   PubMed Web of Science ®Google Scholar
• Sullivan R, Fredette J P, Socinski M, Elias A, Antman K, Schnipper L, Griffin J D. Enhancement of superoxide anion release by granulocytes harvested from patients receiving granulocyte-macrophage colony-stimulating factor. Br J Haematol 1989; 71: 475–479
   PubMed Web of Science ®Google Scholar
• Jaswon M S, Khwaja A, Roberts P J, Jones H M, Linch D C. The effects of rhGM-CSF on the neutrophil respiratory burst when studied in whole blood. Br J Haemat 1990; 75: 181–187
   PubMed Web of Science ®Google Scholar
• Buescher E S, McLlheran S M, Vadhan-Raj S. Effects of in vivo administration of recombinant human granulocyte-macrophage colony-stimulating factor on human neutrophil chemotaxis and oxygen metabolism. J Inf Dis 1988; 158: 1140–1142
   PubMed Web of Science ®Google Scholar
• Verhoef G, Boogaerts M. In vivo administration of granulocyte-macrophage colony stimulating factor enhances neutrophil function in patients with myelodysplastic syndromes. Br J Haematol 1991; 79: 177–184
   PubMed Web of Science ®Google Scholar
• Bober L A, Grace M J, Pugliese-Sivo C, Rojas-Triana A, Waters T, Sullivan L M, Narula S K. The effect of GM-CSF and G-CSF on human neutrophil function. Immunopharma-co1 1995; 29: 111–119
   PubMed Web of Science ®Google Scholar
• Grabstein K H, Urdal D L, Tushinski R J, Mochizuki D Y, Price V L, Cantrell M A, Gillis S, Conlon P J. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science 1986; 232: 506–508
   PubMed Web of Science ®Google Scholar
• Charak B S, Agah R, Mazumder A. Granulocyte-macrophage colony-stimulating factor-induced antibody-dependent cellular cytotoxicity in bone marrow macrophages: application in bone marrow transplantation. Blood 1993; 81: 3474–3479
   PubMed Web of Science ®Google Scholar
• Fabian I, Kletter Y, Slavin S. Therapeutic potential of recombinant granulocyte-macrophage colony-stimulating factor and interleukin-3 in murine B-cell leukemia. Blood 1988; 72: 913–918
   PubMed Web of Science ®Google Scholar
• Steward W P, Scarffe J H, Austin R, Bonnem E, Thatcher N, Morgenstern G, Crowther D. Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions - a phase I dose-toxicity study. Br J Cancer 1989; 59: 142–145
   PubMed Web of Science ®Google Scholar
• Ragnhammar P, Fagerberg J, Frbdin J E, Hjelm A L, Linde-Malm C, Magnusson I, Masucci G, Mellstedt H. Effect of monoclonal antibody 17–1A and GM-CSF in patients with advanced colorectal carcinoma - long-lasting, complete remissions can be induced. Int J Cancer 1993; 53: 751–758
   PubMed Web of Science ®Google Scholar
• Edmonson J H, Long H J, Kvols L K. Cytotoxic drugs plus subcutaneous granulocyte-macrophage colony-stimulating factor: can molgramostim enhance antisarcoma therapy?. J Nat Cancer Inst 1994; 86: 312–314
   PubMed Web of Science ®Google Scholar
• Gerhartz H H, Engelhard M, Meusers P, et al. Randomized, double-blind, placebo-controlled, phase HI study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas. Blood 1993; 82: 2329–2339
   PubMed Web of Science ®Google Scholar
• Nash R A, Burstein S A, Storb R, Yang W, Abrams K, Appel-Baum F R, Boone T, Deeg H J, Durack L D, Schuening F G, McDonough S, Moore P, Nelp W B, Slichter S. Thrombocytopenia in dogs induced by granulocyte-macrophage colony-stimulating factor: increased destruction of circulating platelets. Blood 1995; 86: 1765–1775
   PubMed Web of Science ®Google Scholar